

MAINTENANCE OF RESPONSE AT 52-WEEK IN MODERATE TO SEVERE ATOPIC DERMATITIS: A NETWORK META-ANALYSIS OF THERAPEUTIC ALTERNATIVES

AMARO-ÁLVAREZ, L¹; CORDERO-RAMOS, J¹; MORENO-RAMOS, C² ¹HOSPITAL UNIVERSITARIO VIRGEN MACARENA, HOSPITAL PHARMACY, SEVILLA, SPAIN ²SERVICIO EXTREMEÑO DE SALUD, MÉRIDA, SPAIN laura.amaro.sspa@juntadeandalucia.es








Moderate-to-severe atopic dermatitis (AD) can be treated with several therapeutic alternatives. Lebrikizumab has been approved recently.

To develop a network meta-analysis (NMA) to compare the efficacy in maintenance of response at 52-week of biologic treatments for moderate-to-severe AD.

Material and methods



Phase III randomized clinical trials Biologic drugs vs placebo Moderate-to-severe AD.




Baseline characteristics

Age, gender, disease duration EASI, IGA, BSA, NRS, DLQI














R v4.4.1 statistical software $OR \rightarrow Bayesian methods$

Fixed effect model

Results

Study	Drug	Comparator	Age (years)	Gender male %	Disease duration (years)	Follow-up (weeks)	EASI	BSA	DLQI	POEM
ADvocate 1	Lebrikizumab 250mg Q2W	placebo	37.3 ± 17.9	48.5	22.7 ± 14.8	52	30.0 ± 11.9	45.4 (20.0)	15.4 (7.3)	21.3 (5.4)
ADvocate 2	Lebrikizumab 250mg Q2W	placebo	34.5 ± 15.9	48.9	20.5 ± 13.6	52	29.0 ± 9.5	45.2 (21.4)	14.4 (6.3)	20.7 (4.4)
SOLO-CONTINUE	Dupilumab 300mg Q2W	placebo	36 ± 22	53.8	26.0 (16.0-42.0)	52	29.8 (19.2)	50.0 (35.0)	14.0 (12)	22.0 (9,0)
ECZTRA 1	Tralokinumab 300mg Q2W	placebo	37 ± 21	58.2	27.0 (19.0–38.0)	52	28,2 (18.7)	50 (43)	17 (10)	24 (7)
ECZTRA 2	Tralokinumab 300mg Q2W	placebo	34 ± 23	60.5	25.5 (17.0-39.0)	52	28,2 (21)	50 (43)	18 (10)	24 (7)

Treatment	EASI-75 Comparison: other vs 'placebo (Common Effects Model)	o' OR	95%-CI	IGA 0 or 1 Comparison: other vs 'placebo' Treatment (Common Effects Model) OR 95%-CI				
dupilumab 300mg Q2W lebrikizumab 250mg Q2W placebo tralokinumab 300mg Q2W		2.04 [1.00	[3.03; 9.56] [1.02; 4.05] [1.44: 4.80]	dupilumab 300mg Q2W lebrikizumab 250mg Q2W placebo		2.21 [1.00	2.60; 11.80] 1.14; 4.30]	





- This NMA provided a review of efficacy of recent therapies for moderate-to-severe AD focusing on long-term response maintenance.
- Dupilumab 300mg Q2W were the most effective scheme.
- Similar benefit was observed between tralokinumab 300mg Q2W and lebrikizumab 250mg Q2W.
- Further trials are needed to compare long-term outcomes of other therapies, such as JAK inhibitors.



